806 related articles for article (PubMed ID: 27180886)
1. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement.
Turok DK; Eisenberg DL; Teal SB; Keder LM; Creinin MD
Am J Obstet Gynecol; 2016 Nov; 215(5):599.e1-599.e6. PubMed ID: 27180886
[TBL] [Abstract][Full Text] [Related]
2. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
[TBL] [Abstract][Full Text] [Related]
3. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
[TBL] [Abstract][Full Text] [Related]
4. Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion.
Grentzer JM; Peipert JF; Zhao Q; McNicholas C; Secura GM; Madden T
Contraception; 2015 Oct; 92(4):313-8. PubMed ID: 26093189
[TBL] [Abstract][Full Text] [Related]
5. Best practices to minimize risk of infection with intrauterine device insertion.
Caddy S; Yudin MH; Hakim J; Money DM; ;
J Obstet Gynaecol Can; 2014 Mar; 36(3):266-274. PubMed ID: 24612897
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.
Roddy RE; Zekeng L; Ryan KA; Tamoufé U; Weir SS; Wong EL
N Engl J Med; 1998 Aug; 339(8):504-10. PubMed ID: 9709043
[TBL] [Abstract][Full Text] [Related]
7. Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial.
Kakaire O; Byamugisha JK; Tumwesigye NM; Gemzell-Danielsson K
Hum Reprod; 2015 Jul; 30(7):1573-9. PubMed ID: 25979373
[TBL] [Abstract][Full Text] [Related]
8. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use.
Darney PD; Stuart GS; Thomas MA; Cwiak C; Olariu A; Creinin MD
Contraception; 2018 Mar; 97(3):210-214. PubMed ID: 29038072
[TBL] [Abstract][Full Text] [Related]
9. Subsequent sexually transmitted infection after outpatient treatment of pelvic inflammatory disease.
Trent M; Chung SE; Forrest L; Ellen JM
Arch Pediatr Adolesc Med; 2008 Nov; 162(11):1022-5. PubMed ID: 18981349
[TBL] [Abstract][Full Text] [Related]
10. Testing for sexually transmitted infections at intrauterine device insertion: an evidence-based approach.
Sufrin CB; Averbach SH
Clin Obstet Gynecol; 2014 Dec; 57(4):682-93. PubMed ID: 25222531
[TBL] [Abstract][Full Text] [Related]
11. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease.
Sufrin CB; Postlethwaite D; Armstrong MA; Merchant M; Wendt JM; Steinauer JE
Obstet Gynecol; 2012 Dec; 120(6):1314-21. PubMed ID: 23168755
[TBL] [Abstract][Full Text] [Related]
12. Unprotected intercourse in the 2 weeks prior to requesting emergency intrauterine contraception.
Sanders JN; Howell L; Saltzman HM; Schwarz EB; Thompson IS; Turok DK
Am J Obstet Gynecol; 2016 Nov; 215(5):592.e1-592.e5. PubMed ID: 27349294
[TBL] [Abstract][Full Text] [Related]
13. The safety of intrauterine contraception initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections.
Jatlaoui TC; Simmons KB; Curtis KM
Contraception; 2016 Dec; 94(6):701-712. PubMed ID: 27263041
[TBL] [Abstract][Full Text] [Related]
14. Same-day intrauterine device placement is rarely complicated by pelvic infection.
Papic M; Wang N; Parisi SM; Baldauf E; Updike G; Schwarz EB
Womens Health Issues; 2015; 25(1):22-7. PubMed ID: 25445666
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use.
Creinin MD; Schreiber CA; Turok DK; Cwiak C; Chen BA; Olariu AI
Am J Obstet Gynecol; 2022 Dec; 227(6):871.e1-871.e7. PubMed ID: 35569516
[TBL] [Abstract][Full Text] [Related]
16. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
[TBL] [Abstract][Full Text] [Related]
17. The Additive Value of Pelvic Examinations to History in Predicting Sexually Transmitted Infections for Young Female Patients With Suspected Cervicitis or Pelvic Inflammatory Disease.
Farrukh S; Sivitz AB; Onogul B; Patel K; Tejani C
Ann Emerg Med; 2018 Dec; 72(6):703-712.e1. PubMed ID: 30251627
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Trial Comparing the Treatment of Patients Tested for Chlamydia and Gonorrhea After a Rapid Polymerase Chain Reaction Test Versus Standard of Care Testing.
May L; Ware CE; Jordan JA; Zocchi M; Zatorski C; Ajabnoor Y; Pines JM
Sex Transm Dis; 2016 May; 43(5):290-5. PubMed ID: 27100764
[TBL] [Abstract][Full Text] [Related]
19. Intrauterine Devices in the Context of Gonococcal Infection, Chlamydial Infection, and Pelvic Inflammatory Disease: Not Mutually Exclusive.
Esposito CP
J Midwifery Womens Health; 2020 Jul; 65(4):562-566. PubMed ID: 32592523
[TBL] [Abstract][Full Text] [Related]
20. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
